[go: up one dir, main page]

TN2011000327A1 - Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals - Google Patents

Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals

Info

Publication number
TN2011000327A1
TN2011000327A1 TN2011000327A TN2011000327A TN2011000327A1 TN 2011000327 A1 TN2011000327 A1 TN 2011000327A1 TN 2011000327 A TN2011000327 A TN 2011000327A TN 2011000327 A TN2011000327 A TN 2011000327A TN 2011000327 A1 TN2011000327 A1 TN 2011000327A1
Authority
TN
Tunisia
Prior art keywords
fullerene
prolong
mammals
expected lifespan
maintain good
Prior art date
Application number
TN2011000327A
Other languages
English (en)
Inventor
Fathi Moussa
Tarek Baati
Manef Abderrabba
Original Assignee
Fathi Moussa
Manef Abderrabba
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Fathi Moussa, Manef Abderrabba filed Critical Fathi Moussa
Priority to TN2011000327A priority Critical patent/TN2011000327A1/fr
Priority to CN201810244329.0A priority patent/CN108542914A/zh
Priority to CN201280037654.0A priority patent/CN103826472A/zh
Priority to US14/130,020 priority patent/US20140140985A1/en
Priority to EP12780896.2A priority patent/EP2725926A1/fr
Priority to PCT/TN2012/000003 priority patent/WO2013025180A1/fr
Publication of TN2011000327A1 publication Critical patent/TN2011000327A1/fr
Priority to US15/927,703 priority patent/US11471484B2/en
Priority to US18/047,181 priority patent/US20230060379A1/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23BPRESERVATION OF FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES; CHEMICAL RIPENING OF FRUIT OR VEGETABLES
    • A23B2/00Preservation of foods or foodstuffs, in general
    • A23B2/70Preservation of foods or foodstuffs, in general by treatment with chemicals
    • A23B2/725Preservation of foods or foodstuffs, in general by treatment with chemicals in the form of liquids or solids
    • A23B2/788Inorganic compounds
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23DEDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D7/00Edible oil or fat compositions containing an aqueous phase, e.g. margarines
    • A23D7/005Edible oil or fat compositions containing an aqueous phase, e.g. margarines characterised by ingredients other than fatty acid triglycerides
    • A23D7/0053Compositions other than spreads
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23DEDIBLE OILS OR FATS, e.g. MARGARINES, SHORTENINGS OR COOKING OILS
    • A23D9/00Other edible oils or fats, e.g. shortenings or cooking oils
    • A23D9/007Other edible oils or fats, e.g. shortenings or cooking oils characterised by ingredients other than fatty acid triglycerides
    • AHUMAN NECESSITIES
    • A23FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23LFOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/44Elemental carbon, e.g. charcoal, carbon black
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00General protective or antinoxious agents
    • A61P39/06Free radical scavengers or antioxidants

Landscapes

  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Toxicology (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
TN2011000327A 2011-06-30 2011-06-30 Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals TN2011000327A1 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
TN2011000327A TN2011000327A1 (en) 2011-06-30 2011-06-30 Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals
CN201810244329.0A CN108542914A (zh) 2011-06-30 2012-06-28 富勒烯及其保持哺乳动物身体健康和延长哺乳动物预期寿命的用途
CN201280037654.0A CN103826472A (zh) 2011-06-30 2012-06-28 富勒烯及其保持哺乳动物身体健康和延长哺乳动物预期寿命的用途
US14/130,020 US20140140985A1 (en) 2011-06-30 2012-06-28 Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals
EP12780896.2A EP2725926A1 (fr) 2011-06-30 2012-06-28 [60]fullerène et son utilisation pour maintenir des mammifères en bonne santé et prolonger leur durée de vie espérée
PCT/TN2012/000003 WO2013025180A1 (fr) 2011-06-30 2012-06-28 [60]fullerène et son utilisation pour maintenir des mammifères en bonne santé et prolonger leur durée de vie espérée
US15/927,703 US11471484B2 (en) 2011-06-30 2018-03-21 Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals
US18/047,181 US20230060379A1 (en) 2011-06-30 2022-10-17 Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
TN2011000327A TN2011000327A1 (en) 2011-06-30 2011-06-30 Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals

Publications (1)

Publication Number Publication Date
TN2011000327A1 true TN2011000327A1 (en) 2012-12-17

Family

ID=54696184

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000327A TN2011000327A1 (en) 2011-06-30 2011-06-30 Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals

Country Status (5)

Country Link
US (3) US20140140985A1 (fr)
EP (1) EP2725926A1 (fr)
CN (2) CN108542914A (fr)
TN (1) TN2011000327A1 (fr)
WO (1) WO2013025180A1 (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TN2011000327A1 (en) 2011-06-30 2012-12-17 Fathi Moussa Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals
CN104997646A (zh) * 2015-07-09 2015-10-28 北京福纳康生物技术有限公司 一种富勒烯油溶性溶液及其制备方法
WO2017125080A1 (fr) * 2016-01-21 2017-07-27 北京福纳康生物技术有限公司 Application de fullerène/métal-fullerène dans la préparation d'un produit pharmaceutique
CN106109494A (zh) * 2016-08-11 2016-11-16 中国科学院化学研究所 预防和/或治疗骨髓抑制的微纳材料及其应用
CN105596368B (zh) * 2016-02-01 2019-04-16 北京福纳康生物技术有限公司 一种富勒烯橄榄油组合物及其在治疗帕金森病中的应用
US10342797B2 (en) * 2016-03-13 2019-07-09 LivePet, LLC Solubility of therapeutic agents
CN107753513A (zh) * 2016-08-15 2018-03-06 北京福纳康生物技术有限公司 富勒烯在制备药物中的用途以及保护肝脏的药物
CN106509161A (zh) * 2016-10-24 2017-03-22 厦门福慈生物科技有限公司 一种抗氧化食用油及其制备方法
CN106680230B (zh) * 2017-01-06 2019-10-22 北京福纳康生物技术有限公司 一种富勒烯油中c60或c70的含量测定方法
CN109481463B (zh) * 2017-09-12 2021-04-06 北京福纳康生物技术有限公司 一种口服富勒烯乳剂、制备方法及应用
CN109481464B (zh) * 2017-09-12 2021-04-09 北京福纳康生物技术有限公司 一种注射用富勒烯乳剂及其制备方法
CA3079723A1 (fr) * 2017-10-16 2019-04-25 Joshua Raderman Formulations de cannabinoides et procedes comprenant l'antioxydant c60
RU2679257C1 (ru) * 2018-01-17 2019-02-06 Общество с ограниченной ответственностью "С60Био" Способ получения высококонцентрированного водного раствора фуллерена
CN108497099A (zh) * 2018-03-27 2018-09-07 厦门福慈生物科技有限公司 富勒烯被用于制备成富勒烯微囊粉的用途
WO2019184419A1 (fr) * 2018-03-27 2019-10-03 厦门福慈生物科技有限公司 Utilisation d'un composé de fullerène, poudre de microcapsule de fullerène et son procédé de préparation et application associée
US11344528B2 (en) * 2021-01-13 2022-05-31 Louis Dischler Compositions for promoting the endogenous self-renewal of stem cells
US11090320B2 (en) 2018-08-18 2021-08-17 Louis Dischler Compositions for reducing mitochondrial dysfunction
US11317646B2 (en) 2018-08-18 2022-05-03 Louis Dischler Methods and compositions for rapidly decreasing epigenetic age and restoration of more youthful function
US11541022B2 (en) 2018-08-18 2023-01-03 Louis Dischler Methods and compositions for the treatment of neurological diseases and syndromes of aging
US20200188339A1 (en) 2018-12-14 2020-06-18 Max Champie Nutraceutical Composition Comprising C60 And Ketone Esters
US11179350B2 (en) 2018-12-14 2021-11-23 Max Champie Nutraceutical compositions comprising C60 and Cox-2 inhibitor
US20210145762A1 (en) * 2019-11-15 2021-05-20 Redox Balance Llc Methods of treating oxidative stress to modulate redox balance, preventing oxidative stress induced cell damage and death
US11504351B2 (en) 2021-02-16 2022-11-22 Louis Dischler Methods for restoring stem cell pools and reducing epigenetic age
US12274713B2 (en) 2021-05-07 2025-04-15 Max C. Champie Nutraceutical composition comprising a water-soluble fullerene and a ketone
US20230287577A1 (en) * 2022-03-12 2023-09-14 Razor Keep, LLC Blade Preserving Products and Methods for Manufacturing
WO2024229379A1 (fr) * 2023-05-03 2024-11-07 Best Planet Science Llc Formulations aqueuses comprenant du fullerène, de l'eau structurée, de l'hydrogène gazeux dissous, des minéraux et des additifs

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5648523A (en) 1995-10-26 1997-07-15 Chiang Long Y Fullerene derivatives as free-radical scavengers
TWI250874B (en) * 2000-03-24 2006-03-11 Nat Health Research Institutes Pharmaceutical compositions for preventing or treating disorders associated with bacterial or viral infection
JP4293735B2 (ja) 2001-01-19 2009-07-08 三栄源エフ・エフ・アイ株式会社 フラーレン誘導体およびそれからなる組成物
US20030162837A1 (en) * 2002-02-23 2003-08-28 Dugan Laura L. Carboxyfullerenes and methods of use thereof
WO2005105214A1 (fr) * 2004-05-04 2005-11-10 Universite Paris Sud Compositions comportant des fullerenes hydrosolubles et leur utilisation pour la prevention de degats causes par des radicaux libres
JP2006160664A (ja) 2004-12-07 2006-06-22 Vitamin C60 Bioresearch Kk フリーラジカル疾患予防治療用組成物
WO2009114089A2 (fr) 2008-03-03 2009-09-17 Luna Innovations Incorporated Utilisation de fullerenes pour augmenter et stimuler la croissance capillaire
TN2009000493A1 (en) 2009-11-25 2011-03-31 Fathi Moussa Oily solutions of c [60] fullerene and their use for preventing damages caused to meatazoans by free radicals
US20120171121A1 (en) 2011-01-04 2012-07-05 Brown University Rosette Nanotubes as Drug Delivery Agents
TN2011000327A1 (en) 2011-06-30 2012-12-17 Fathi Moussa Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals
UA102139C2 (ru) 2011-08-16 2013-06-10 Киевский Национальный Университет Имени Тараса Шевченко Способ лечения злокачественных опухолей комбинацией немодифицированных фуллеренов с60 и доксорубицина
CN103705388A (zh) 2013-12-19 2014-04-09 深圳市通产丽星股份有限公司 一种富勒烯胶囊及其应用
EP3116392A4 (fr) 2014-03-14 2018-02-14 Rhode Island Hospital Nanovecteurs et leur traitement pour le diagnostic et la thérapeutique

Also Published As

Publication number Publication date
US11471484B2 (en) 2022-10-18
EP2725926A1 (fr) 2014-05-07
WO2013025180A1 (fr) 2013-02-21
US20230060379A1 (en) 2023-03-02
US20180271906A1 (en) 2018-09-27
US20140140985A1 (en) 2014-05-22
CN103826472A (zh) 2014-05-28
CN108542914A (zh) 2018-09-18

Similar Documents

Publication Publication Date Title
TN2011000327A1 (en) Fullerene and its use to maintain good health and to prolong the expected lifespan of mammals
MX384514B (es) Derivados citotoxicos de la benzodiazepina.
MX2013004491A (es) Boronatos como inhibidores de arginasa.
AR081681A1 (es) METODOS Y COMPOSICIONES PARA LA ADMINISTRACION INTRATECAL DE b-GALACTOCEREBROSIDASA
MY163275A (en) Ibat inhibitors for the treatment of liver diseases
HK1211208A1 (zh) 細胞毒性苯並二氮呯衍生物
PH12013502284A1 (en) Protein-active agent conjugates and method for preparing the same
MY164731A (en) Compound
GEP20146053B (en) Compounds expanding hematopoietic stem cells
MY184978A (en) Pyridin-2-amides useful as cb2 agonists
UA111065C2 (uk) Композиції норибогаїну
PH12014500126A1 (en) 4-piperidinyl compounds for use as tankyrase inhibitors
SG10201901824UA (en) Cytotoxic benzodiazepine derivatives
PH12013501688A1 (en) Treatment of amyotrophic lateral sclerosis using umbilical derived cells
MX2019012939A (es) Formulaciones que contienen linaclotida para administracion oral.
NZ607149A (en) Galacto-oligosaccharide-containing composition and a method of producing it
MX2011013032A (es) Inhibidores de fosfatidilinositol 3-cinasa.
NZ708821A (en) Lfa-1 inhibitor formulations
MX2011011229A (es) Metodo para reducir la presion intraocular en los seres humanos.
PH12012501098A1 (en) 7-[3,5-dihydroxy-2- (3-hydroxy-5-phenyl-pent-1-enyl)- cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
MY163476A (en) Oral care compositions
MX2011008645A (es) Inhibidores de tetrahidrotiazolopiridina de fosfatidilinositol 3 cinasa.
MX347541B (es) Analogos de acido sialico.
EA201391586A1 (ru) ИНГИБИТОРЫ 17α-ГИДРОКСИЛАЗЫ/C-ЛИАЗЫ
UA103197C2 (uk) Застосування ніфуртимоксу для лікування хвороб, спричинених трихомонадами